Key points
- Cantor Fitzgerald initiates Tempus AI at $80
- Stock rose 47% after trial data boosted acquisition target Personalis
- Most August insider sales were tax withholding
Cantor Fitzgerald began coverage of Tempus AI (TEM) at overweight with an $80 price target on Wednesday, the second bullish call on the precision medicine company in two days. Tempus closed Wednesday at $61.94, below Tuesday's $62.27. Cantor's $80 target implies 28 percent upside from the Tuesday close its note was written against, with bull case upside of 59 percent.
The mean price target among analysts polled by FactSet is $65.79, according to MT Newswires. Piper Sandler upgraded Tempus to overweight from neutral on Tuesday and raised its target to $76 from $56, having cut that same target to $56 on August 4. BTIG lifted its target to $80 from $70 on August 20.
What is Cantor's argument?
Cantor's $80 rests on which companies Tempus should be measured against. Cantor argues the Data and Applications segment is priced like a life sciences data vendor when its growth and margins look like a software platform.
"Tempus' D&A segment is mispriced against the wrong peer group, in our view," the analysts wrote. The note has the diagnostics business trading in line with its own comparables at 6.6 times 2028 enterprise value to revenue, a group including Caris Life Sciences (CAI), Guardant Health (GH), Natera (NTRA) and NeoGenomics (NEO).
Data and Applications is the piece Cantor says is wrong. The market prices its "26% growth and 76% gross margin off decelerating staffing and hardware-heavy data-vendor peers" at 6.1 times, the note says, naming IQVIA (IQV), Veeva Systems (VEEV), 10x Genomics (TXG) and Certara (CERT). Cantor would price it against Palantir (PLTR), Snowflake (SNOW), Datadog (DDOG) and Reddit (RDDT) at 11.7 times.
What drove the stock up 47 percent?
Tempus closed at $49.36 on August 18. It had reported its first quarterly profit earlier in the month. Three sessions later it closed at $72.69. Volume ran above 15 million shares on each of those three days, against daily turnover that had been running between 2 million and 6 million shares earlier in the month.
The move followed Phase 3 results that Merck (MRK) and Moderna (MRNA) announced on August 19. Their intismeran autogene, a custom mRNA therapy, paired with Merck's Keytruda, improved recurrence-free survival in patients with resected melanoma. It was the first positive Phase 3 readout for a personalized mRNA cancer treatment, and it also sent four Korean stocks to their 30 percent daily limit the next morning.
The therapy requires sequencing each patient's tumor to identify the neoantigens a dose is built around. Moderna uses technology from Personalis (PSNL) for that step. Tempus agreed on July 20 to buy Personalis.
Tempus does not own Personalis yet
Tempus already held 12.5 percent of Personalis, 13,039,067 shares, as of a July 19 filing, and agreed the following day to buy the rest. That purchase has not closed.
Personalis shareholders are to receive $16.25 per share. The default form of payment is all stock, at a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share. Tempus separately holds the option to pay cash instead, at its own discretion, for up to half of the total consideration. The two terms do not conflict: the deal is a 100 percent stock transaction unless Tempus elects cash, and any such election stops at 50 percent. The companies put enterprise value at $1.5 billion, a figure stated net of the stake Tempus already owns, and expect to close in late 2026 or early 2027, subject to a Personalis shareholder vote and regulatory approvals.
The merger agreement also gives Personalis the right to terminate if the market price of Tempus Class A stock falls below $46.00 before closing. Personalis closed Wednesday at $16.73, above the $16.25 figure in the agreement.
"MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored," Tempus chief executive Eric Lefkofsky said when the deal was announced. MRD stands for molecular residual disease, the small amount of cancer that can remain in a patient after treatment.
What did the insider filings actually show?
Four Tempus executives filed Form 4s covering sales on August 18 and 19 worth about $12.9 million in total. About $10.8 million of that was automatic tax withholding, and the remaining $2.0 million came from trading plans adopted a year earlier.
Lefkofsky sold 132,591 shares on August 18 at a weighted average price of $49.61. The filing's footnote says those shares represent the amount "required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units," that the sale is "mandated by the Issuer's election under its equity incentive plans," and that it "does not represent a discretionary sale by the Reporting Person." The same footnote appears on the August 18 sale in all four filings.
Two sales were genuine plan sales. Chief financial officer James Rogers sold 26,313 shares at $60.00 on August 19 under a Rule 10b5-1 trading plan he adopted on September 11, 2025. Chief legal officer Andrew Polovin sold 7,927 shares at $56.00 the same day under a plan adopted on August 12, 2025. Both plans predate the Merck and Moderna readout by about a year.
| Insider | Title | Shares | Price | Date | Type |
|---|
| Eric Lefkofsky | CEO and Chairman | 132,591 | $49.61 | Aug 18 | Tax withholding |
| Ryan Fukushima | CEO, Data | 41,095 | $49.61 | Aug 18 | Tax withholding |
| James Rogers | Chief Financial Officer | 22,529 | $49.61 | Aug 18 | Tax withholding |
| Andrew Polovin | Chief Legal Officer | 22,148 | $49.61 | Aug 18 | Tax withholding |
| James Rogers | Chief Financial Officer | 26,313 | $60.00 | Aug 19 | 10b5-1 plan, adopted Sept 11, 2025 |
| Andrew Polovin | Chief Legal Officer | 7,927 | $56.00 | Aug 19 | 10b5-1 plan, adopted Aug 12, 2025 |
Four Applied Digital insiders filed the same kind of withholding sale in early August, alongside a director who sold $2.34 million outright.
What Tempus itself did during the run
The company's own contribution arrived a session after the three-day move ended. Tempus received 510(k) clearance from the Food and Drug Administration on August 24 for ECG-PH, software that reads a standard 12-lead electrocardiogram for signs of pulmonary hypertension. It is cleared for patients 40 and older who have cardiovascular symptoms and no known history of the disease, and it joins the company's cleared products for atrial fibrillation and low ejection fraction. The stock fell 9 percent that day.
Supply ran the other way through the same stretch. Ark Invest, which held Tempus at 4.94 percent of the ARK Innovation ETF and 6.86 percent of the ARK Genomic Revolution ETF as of an August 24 tally by Benzinga, sold 57,819 shares on August 25 and another 250,062 on September 1, the second sale worth about $15.6 million at that day's close. Tempus closed Wednesday about 15 percent below the $72.69 it reached on August 21.
The two halves of the bull case sit awkwardly together. Cantor's $80 rests on re-rating Data and Applications, a segment that is already inside Tempus and already producing the growth and margin the note cites. The 47 percent August move rested on Personalis, which is not inside Tempus and will not be until a shareholder vote and regulatory clearances land, some time between late this year and early next.
A buyer at $61.94 is paying for both. Only one of them is a business Tempus controls today.
